Resmed has received clearance from the U.S. Food and Drug Administration (FDA) for an artificial intelligence (AI)-enabled ...
Resmed believes its artificial intelligence-powered approach to personalizing the settings of its connected CPAP machines can lead to better sleep for people with obstructive apnea. Now the FDA has ...
SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has ...
SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has ...
ResMed has secured FDA clearance for its Personalized Therapy Comfort Settings (PTCS), branded as Smart Comfort - a significant step in sleep apnea treatment.
Resmed gains FDA's nod for Smart Comfort, an AI-driven CPAP tool boosting sleep therapy personalization and adherence.
Expands ResMed’s out-of-hospital software portfolio into skilled nursing and senior living verticals Enhances ResMed’s ability to improve patient transitions of care and provider efficiencies Purchase ...
(MENAFN- GlobeNewsWire - Nasdaq) Technology uses real-world sleep data and machine learning to help people with sleep apnea start and stay on therapy SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- ...
SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results